No, actually, my price target is significantly higher based on the 15,000 patients worldwide and $300K/year price tag, driving to $4.5B/year as the potential revenue amount.
(This is where you rehash your outdated data and pretend that the incident rate of HoFH is only 1 in one million based on your Wiki article that was using 1970 studies as the basis - and then you refuse to do any other due diligence and refuse to acknowledge that the company based their 15,000 number off of actual reported cases diagnosed by doctors worldwide). So, in short, post your ignorance again and again.
Too bad you got wiped out from $15 to $60 on your short position, you could have made a bundle from $100 to $55, but you had nothing left to invest. LOL.